Evidence map›Paper›PMID 32564458›Full record

SynthesisBJU international2021

The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.

Reza Sari Motlagh, Keiichiro Mori, Noriyoshi Miura, Fahad Quhal, Abdulmajeed Aydh, Ekaterina Laukhtina, Benjamin Pradere, Pierre I Karakiewicz, Dmitry V Enikeev, Marina Deuker and 1 more

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BJU international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 11 countries.

Reza Sari MotlaghDepartment of Urology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-3819-9911
Keiichiro MoriDepartment of Urology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6147-6569
Noriyoshi MiuraDepartment of Urology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-2229-0948
Fahad QuhalDepartment of Urology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-8163-6953
Abdulmajeed AydhDepartment of Urology, Medical University of Vienna, Vienna, Austria.
Ekaterina LaukhtinaDepartment of Urology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-8953-0272
Benjamin PradereDepartment of Urology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-7768-8558
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
Dmitry V EnikeevInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.ORCID 0000-0001-7169-2209
Marina DeukerCancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.ORCID 0000-0002-1219-387X
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6627-6179
Sechenov University · RUEhime University · JPGoethe University Frankfurt · DEJikei University School of Medicine · JPKing Fahad Specialist Hospital · SAKing Fahd Medical City · SAMedical University of Vienna · ATUniversité de Montréal · CAUniversité de Tours · FRUniversity of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate recurrence and progression risk after simultaneous endoscopic surgery of bladder cancer and benign prostatic hyperplasia (BPH), as simultaneous surgery is not an unusual scenario and theoretically simultaneous transurethral resection of bladder tumour (TURBT) and transurethral resection of the prostate (TURP) can lead to an increased risk of recurrence in the bladder neck and prostatic urethra (BN/PU).

methodsWe conducted a systematic review and meta-analysis to assess the risk of recurrence (i.e. whole bladder and/or BN/PU) and tumour progression as outcomes after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone. We queried PubMed and Web of Science database on 1 January 2020. We used random- and/or fixed-effects meta-analytic models in the presence or absence of heterogeneity according to the I

resultsNine retrospective and three clinical trial studies were selected after considering inclusion and exclusion criteria. We conducted the meta-analysis on retrospective and randomised controlled trials (RCTs) separately. Eight retrospective and three RCT studies were included to assess the BN/PU recurrence risk and the summarised risk ratio (RR) was 1.02 (95% confidence interval [CI] 0.74-1.41) and 0.93 (95% CI 0.47-1.84), respectively. Five retrospective and two RCT studies were included to assess the progression risk and the summarised RR was 0.91 (95% CI 0.56-1.48) and 1.16 (95% CI 0.30-4.51), respectively. Eight retrospective and three RCT studies were included to assess the whole bladder recurrence risk and the summarised RR was 0.87 (95% CI 0.78-0.97) and 0.89 (95% CI 0.65-1.21), respectively.

conclusionWe did not observe any increased risk of total bladder recurrence, BN/PU recurrence, or progression after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone.

Indexed as

CystectomyHumansMaleNeoplasm Recurrence, LocalProstatic HyperplasiaTransurethral Resection of ProstateUrinary BladderUrinary Bladder Neoplasmsbenign prostatic hyperplasiabladder cancer#BladderCancer#blcsmendoscopic surgerysimultaneous surgeryTURBTTURP

Identifiers

PMID32564458
PMCPMC7891376
OpenAlexW3036494572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.